Table 2.

Selected potential combination approaches undergoing clinical evaluation include dual T-cell checkpoint inhibition and combinations with VEFG targeted agents.

Combination regimen	Treatment groups	Phase	Trial number
PD-1 and VEGF inhibition	Pembrolizumab with axitinib	I	NCT02133742
	Pembrolizumab with Pazopanib	I/II	NCT02014636
	Nivolumab with sunitinib vs. nivolumab with pazopanib	I	NCT01472081
PD-1 and CTLA4 inhibition	Prembrolizumab vs. pembrolizumab with ipilimumab vs. pembrolizumab with peglylated IFN-a2b	I/II	NCDT02089685
	Nivolumab vs. nivolumab with bevacizumab vs. nivolumab with ipilimumab	II	NCT02210117
	Nivolumab with ipilimumab vs. sunitinib	II	NCT02231749
PD-L1 and VEGF inhibition	MPDL3280A vs. MPDL3280A with bevacizumab vs. MPDL3280A with sunitinib	II	NCT01984242